Table 3. Clinical risk factors for cancer-related PTSS and severe PTSSa.
3 Months post surgery
|
15 Months post surgery
|
|||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
PTSS | Severe PTSS |
Severe PTSS age adjusted
|
Severe PTSS fully adjusted
b
|
PTSS | Severe PTSS |
Severe PTSS age adjusted
|
Severe PTSS fully adjusted
c
|
|||||||
N | Mean (s.d.) | (%) | OR | (95% CI) | OR | (95% CI) | N | Mean (s.d.) | (%) | OR | (95% CI) | OR | (95 % CI) | |
Tumour size | P=0.85 | P=0.45 | P=0.45 | P=0.58 | P=0.35 | P=0.35 | P=0.36 | P=0.46 | ||||||
⩽20 mm | 2009 | 19.99 (15.74) | 19.5 | 1.00 | (Referent) | 1.00 | (Referent) | 1790 | 15.89 (15.19) | 13.5 | 1.00 | (Referent) | 1.00 | (Referent) |
>20 mm and ⩽50 mm | 1187 | 20.37 (16.14) | 21.3 | 1.12 | 0.94–1.34 | 1.10 | 0.92–1.32 | 1019 | 16.83 (15.66) | 15.5 | 1.17 | 0.94–1.46 | 1.15 | 0.92–1.44 |
>50 mm | 101 | 20.33 (14.87) | 19.8 | 1.05 | 0.63–1.73 | 1.04 | 0.62–1.73 | 85 | 16.51 (14.55) | 14.1 | 1.05 | 0.56–1.97 | 0.98 | 0.52–1.86 |
Nodal status | P<0.001 | P<0.001 | P<0.001 | P<0.001 | P<0.001 | P<0.001 | P<0.001 | P<0.001 | ||||||
0 | 1632 | 18.89 (15.40) | 17.4 | 1.00 | (Referent) | 1.00 | (Referent) | 1467 | 15.28 (14.99) | 12.3 | 1.00 | (Referent) | 1.00 | (Referent) |
1–3 | 1080 | 20.63 (15.83) | 21.3 | 1.30 | 1.07–1.58 | 1.30 | 1.06–1.59 | 968 | 16.22 (15.20) | 14.0 | 1.16 | 0.92–1.48 | 1.17 | 0.91–1.49 |
>3 | 594 | 22.58 (16.77) | 25.4 | 1.68 | 1.34–2.11 | 1.61 | 1.28–2.03 | 468 | 19.24 (16.32) | 20.5 | 1.84 | 1.40–2.42 | 1.81 | 1.37–2.40 |
Tumour grade | P=0.82 | P=0.88 | P=0.98 | P=0.99 | P=0.02 | P=0.26 | P=0.26 | P=0.46 | ||||||
I | 789 | 19.92 (16.21) | 20.0 | 1.00 | (Referent) | 1.00 | (Referent) | 725 | 15.41 (15.33) | 13.2 | 1.00 | (Referent) | 1.00 | (Referent) |
II | 1189 | 20.35 (15.90) | 20.4 | 1.04 | 0.83–1.30 | 1.01 | 0.80–1.27 | 1043 | 16.85 (15.86) | 16.0 | 1.25 | 0.95–1.64 | 1.20 | 0.91–1.59 |
III | 686 | 20.23 (15.60) | 19.1 | 1.01 | 0.78–1.31 | 0.99 | 0.75–1.29 | 564 | 17.09 (14.82) | 13.7 | 1.04 | 0.75–1.44 | 1.04 | 0.75–1.45 |
Non-ductal carcinoma | 624 | 19.95 (15.66) | 20.8 | 1.05 | 0.81–1.36 | 1.03 | 0.79–1.34 | 557 | 15.26 (14.87) | 13.1 | 0.99 | 0.71–1.37 | 0.98 | 0.70–1.37 |
ER/PR receptor status | P=0.82 | P=0.88 | P=0.69 | P=0.76 | P=0.15 | P=0.62 | P=0.60 | P=64 | ||||||
ER and PR negative | 615 | 20.21 (15.78) | 20.3 | 1.00 | (Referent) | 1.00 | (Referent) | 485 | 16.93 (15.10) | 14.8 | 1.00 | (Referent) | 1.00 | (Referent) |
ER or PR positive | 2672 | 20.09 (15.88) | 20.1 | 0.96 | 0.77–1.19 | 0.97 | 0.77–1.21 | 2401 | 16.04 (15.37) | 14.0 | 0.93 | 0.71–1.22 | 0.94 | 0.70–1.24 |
Type of surgery | P=0.55 | P=0.47 | P=0.49 | P=0.87 | P=0.31 | P=0.04 | P=0.04 | P=0.12 | ||||||
Mastectomy | 1795 | 20.36 (16.14) | 20.6 | 1.00 | (Referent) | 1.00 | (Referent) | 1555 | 16.62 (15.79) | 15.4 | 1.00 | (Referent) | 1.00 | (Referent) |
Lumpectomy | 1515 | 19.82 (15.48) | 19.5 | 0.94 | 0.79–1.12 | 0.99 | 0.83–1.18 | 1351 | 15.75 (14.78) | 12.8 | 0.81 | 0.65–0.99 | 0.84 | 0.68–1.04 |
Chemotherapy | P=0.52 | P=0.15 | P=0.24 | P=0.33 | P<0.001 | P=0.93 | P=0.62 | P=0.58 | ||||||
No chemotherapy | 1871 | 20.18 (16.35) | 21.0 | 1.00 | (Referent) | 1.00 | (Referent) | 1686 | 15.47 (15.83) | 14.2 | 1.00 | (Referent) | 1.00 | (Referent) |
In treatment/treated | 1435 | 20.05 (15.17) | 19.0 | 1.13 | 0.92–1.39 | 1.11 | 0.90–1.38 | 1217 | 17.28 (14.56) | 14.3 | 1.07 | 0.83–1.37 | 1.08 | 0.83–1.40 |
Radiotherapy I | P=0.004 | P=0.02 | P=0.004 | P=0.005 | P=0.09 | P=0.43 | P=0.42 | P=0.31 | ||||||
No radiotherapy | 680 | 18.51 (15.70) | 16.5 | 1.00 | (Referent) | 1.00 | (Referent) | 619 | 15.50 (15.44) | 13.2 | 1.00 | (Referent) | 1.00 | (Referent) |
To be treated after chemotherapy | 1171 | 20.47 (15.09) | 20.2 | 1.56 | 1.20–2.02 | 1.56 | 1.19–2.04 | |||||||
Treated with radiotherapy | 1456 | 20.59 (16.46) | 21.8 | 1.29 | 1.02–1.65 | 1.31 | 1.02–1.67 | 2284 | 16.43 (15.30) | 14.5 | 1.11 | 0.86–1.45 | 1.15 | 0.88–1.50 |
Hormone therapy I | P=0.22 | P=0.02 | P=0.54 | P=0.69 | P=0.06 | P=0.17 | P=0.16 | P=0.26 | ||||||
No hormone therapy | 1223 | 19.55 (15.77) | 19.3 | 1.00 | (Referent) | 1.00 | (Referent) | 1029 | 15.62 (15.20) | 13.0 | 1.00 | (Referent) | 1.00 | (Referent) |
To be treated after chemotherapy | 821 | 19.95 (14.71) | 17.9 | 1.15 | 0.88–1.49 | 1.12 | 0.86–1.47 | |||||||
In treatment | 1243 | 20.83 (16.67) | 22.5 | 1.07 | 0.87–1.31 | 1.04 | 0.84–1.28 | 1861 | 16.58 (15.42) | 14.9 | 1.17 | 0.94–1.46 | 1.14 | 0.91–1.43 |
Abbreviations: CI=confidence interval; ER=estrogen receptor; IES=impact of events scale; OR=odds ratio; PR=progesterone positive; PTSS=post-traumatic stress symptom.
PTSS=IES; severe PTSS=IES total score ⩾35.
Severe PTSS at 3 months post surgery fully adjusted for socio-demographic and health status variables related (P<0.25) to severe PTSS in the univariate and/or age-adjusted analyses (age, marital status, children, education, social status, personal income and household net wealth per person, psychiatric history, and comorbidity).
Severe PTSS at 15 months post surgery fully adjusted for socio-demographic and health status variables related (P<0.25) to severe PTSS in the univariate and/or age-adjusted analyses (age, children, education, social status, personal income and household net wealth, psychiatric history, and comorbidity).
Age- and fully adjusted OR's in bold differs significantly (95% CI) from the reference group (OR=1.00). Missing observations are not shown. As a consequence totals (N) differs slightly.